Molecular Genetic and Pathological Studies of Anal Tumors

Terminated

• Conditions: Colonic Neoplasms; Rectal Cancer; Anal Cancer; Colon Cancer

• Registration Number: NCT00267787
• Lead Sponsor: Stanford University

Brief Summary

Study the Genetics of Anal Cancer

Detailed Description

To determine the status of previously identified anal cancer molecular markers and any correlations with outcome as well as to discover new molecular biomarkers through correlating molecular data with clinical outcome. Study of tissue samples and cells from biopsies of your lesion and blood sample. We hope to learn the role genes and proteins may play in the development of anal cancer. Experiments will be performed using this tissue and blood, include analysis of DNA, analysis of RNA expression levels, analysis of protein levels of important gene products, and development of tissue culture cell lines.

Study Timeline

• Study Start: 2004-09
• Study First Submitted: 2005-12-19
• Study First Submitted QC: 2005-12-19
• Study First Posted: 2005-12-21
• Primary Completion: 2012-12
• Study Completion: 2017-12
• Status Verified: 2018-12
• Last Update Submitted: 2018-12-06
• Last Update Posted: 2018-12-10

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

Inclusion Criteria:

• Patients with anal tumors
• Undergoing surgery for elective colon and rectal surgery

Exclusion Criteria

No other patients other than adult patients with anal cancer or high risk for anal cancer refered to Stanford will be enrolled to the study. No Children will be included to the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Genetic analysis of blood sample as well as tissues , will provide us with any possible tumor marker for a better prognostic indicator.	Annual assessment.

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States